For the quarter ending 2025-09-30, IGC had $651K increase in cash & cash equivalents over the period. -$2,119K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -1,821 | -1,599 |
| Depreciation and amortization | 119 | 141 |
| Common stock-based compensation and expenses, net | 730 | 452 |
| Other non-cash items | -1,055 | -24 |
| Accounts receivables, net | -46 | 53 |
| Inventory | -6 | -11 |
| Deposits and advances | -37 | -183 |
| Claims and advances | -8 | 0 |
| Accounts payable | -303 | 51 |
| Accrued and other liabilities | 93 | -599 |
| Operating lease asset | -53 | -32 |
| Operating lease liability | -3 | -2 |
| Net cash used in operating activities | -2,090 | -1,407 |
| Purchase of property, plant, and equipment | 29 | 8 |
| Sale of property, plant, and equipment | -23 | 702 |
| Investment in short-term investment | 25 | - |
| Acquisition and development of intangible assets | 297 | 114 |
| Net cash from (used) in investing activities | -374 | 580 |
| Repayment of a long-term loan | - | -1 |
| Net proceeds from the issuance of common stock | 3,111 | 852 |
| Repayment of long-term loan | 2 | - |
| Net cash provided by financing activities | 3,110 | 851 |
| Effects of exchange rate changes on cash and cash equivalents | 5 | 25 |
| Net increase in cash and cash equivalents | 651 | 49 |
| Cash and cash equivalents at beginning of period | 405 | - |
| Cash and cash equivalents at end of period | 1,105 | - |
IGC Pharma, Inc. (IGC)
IGC Pharma, Inc. (IGC)